These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages. Deng L; Ibañez LI; Van den Bossche V; Roose K; Youssef SA; de Bruin A; Fiers W; Saelens X PLoS One; 2015; 10(5):e0126650. PubMed ID: 25973787 [TBL] [Abstract][Full Text] [Related]
23. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model. Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234 [TBL] [Abstract][Full Text] [Related]
24. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum. Yang WT; Yang GL; Wang Q; Huang HB; Jiang YL; Shi CW; Wang JZ; Huang KY; Jin YB; Wang CF Antiviral Res; 2017 Feb; 138():9-21. PubMed ID: 27908830 [TBL] [Abstract][Full Text] [Related]
25. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. Kammoun H; Roux X; Raze D; Debrie AS; De Filette M; Ysenbaert T; Mielcarek N; Saelens X; Fiers W; Locht C PLoS One; 2013; 8(3):e59198. PubMed ID: 23555631 [TBL] [Abstract][Full Text] [Related]
27. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination. Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650 [TBL] [Abstract][Full Text] [Related]
28. Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge. Shokouhi H; Farahmand B; Ghaemi A; Mazaheri V; Fotouhi F Virus Res; 2018 Jun; 251():40-46. PubMed ID: 29730305 [TBL] [Abstract][Full Text] [Related]
29. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. Soboleski MR; Gabbard JD; Price GE; Misplon JA; Lo CY; Perez DR; Ye J; Tompkins SM; Epstein SL PLoS One; 2011; 6(7):e21937. PubMed ID: 21789196 [TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens. Elaish M; Kang KI; Xia M; Ali A; Shany SA; Wang L; Jiang X; Lee CW Vaccine; 2015 Sep; 33(38):4901-9. PubMed ID: 26232342 [TBL] [Abstract][Full Text] [Related]
31. Protection against homo and hetero-subtypic influenza A virus by optimized M2e DNA vaccine. Yao Y; Wang H; Chen J; Shao Z; He B; Chen J; Lan J; Chen Q; Chen Z Emerg Microbes Infect; 2019; 8(1):45-54. PubMed ID: 30866759 [TBL] [Abstract][Full Text] [Related]
33. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. Lee YN; Kim MC; Lee YT; Hwang HS; Cho MK; Lee JS; Ko EJ; Kwon YM; Kang SM Vaccine; 2014 Jul; 32(35):4578-4585. PubMed ID: 24951867 [TBL] [Abstract][Full Text] [Related]
34. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Kim MC; Lee JS; Kwon YM; O E; Lee YJ; Choi JG; Wang BZ; Compans RW; Kang SM Antiviral Res; 2013 Sep; 99(3):328-35. PubMed ID: 23811283 [TBL] [Abstract][Full Text] [Related]
35. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548 [TBL] [Abstract][Full Text] [Related]
36. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice. Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200 [TBL] [Abstract][Full Text] [Related]
37. Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection. Padilla-Quirarte HO; Badillo-Godinez O; Gutierrez-Xicotencatl L; Acevedo-Betancur Y; Luna-Andon JD; Montiel-Hernandez JL; Lopez-Guerrero DV; Esquivel-Guadarrama F Vaccine; 2019 May; 37(19):2624-2633. PubMed ID: 30955979 [TBL] [Abstract][Full Text] [Related]
38. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes. Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225 [TBL] [Abstract][Full Text] [Related]
39. Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies. Schotsaert M; Ysenbaert T; Smet A; Schepens B; Vanderschaeghe D; Stegalkina S; Vogel TU; Callewaert N; Fiers W; Saelens X Sci Rep; 2016 Apr; 6():24402. PubMed ID: 27072615 [TBL] [Abstract][Full Text] [Related]
40. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens. Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]